Opatanol

RSS

olopatadine

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Opatanol. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Opatanol.

This EPAR was last updated on 09/01/2019

Authorisation details

Product details
Name
Opatanol
Agency product number
EMEA/H/C/000407
Active substance
olopatadine hydrochloride
International non-proprietary name (INN) or common name
olopatadine
Therapeutic area (MeSH)
Conjunctivitis, Allergic
Anatomical therapeutic chemical (ATC) code
S01GX09
Publication details
Marketing-authorisation holder
Novartis Europharm Limited
Revision
20
Date of issue of marketing authorisation valid throughout the European Union
16/05/2002
Contact address

Elm Park, Merrion Road
Dublin 4
Ireland

Product information

05/10/2018 Opatanol - EMEA/H/C/000407 - IA/0038

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Ophthalmologicals

Therapeutic indication

Treatment of ocular signs and symptoms of seasonal allergic conjunctivitis.

Assessment history

How useful was this page?

Add your rating
Average
1 rating